Accelerated Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in People Living With HIV/AIDS (PLWHA)

Sponsor
Gopalkumar Rakesh (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05295953
Collaborator
(none)
60
2
21

Study Details

Study Description

Brief Summary

To demonstrate whether four sessions of TBS improves attentional bias and craving in PLWHA smokers compared to four sessions of sham stimulation. We hypothesize 4 sessions of TBS to the left DLPFC will significantly improve attentional bias and craving for smoking cues compared to neutral cues in a population of subjects who are smokers with HIV/AIDS compared to sham stimulation.

Condition or Disease Intervention/Treatment Phase
  • Device: TBS
  • Device: Sham TMS
N/A

Detailed Description

The proposed pilot study seeks to explore modulation of attentional bias and tobacco craving in PLWHA with one session of adequately dosed theta burst stimulation (TBS). Results of this trial will spur clinical research to further investigate the use of TBS as an adjunctive smoking cessation aid for PLWHA and could have broad implications for smoking cessation programs. Data obtained from this pilot study will also facilitate resubmission of a grant application examining adjunctive theta burst stimulation (TBS) combined with varenicline for smoking cessation in PLWHA. People living with HIV/AIDS (PLWHA) smoke at nearly three times the rate of the general population. These extraordinary smoking rates are associated with greater AIDS-related morbidity, non-AIDS related morbidity including non-AIDS-defining cancer, cardiovascular disease, pulmonary disease, and mortality. Smoking significantly impacts the progression and outcome of HIV disease and has been identified as the leading contributor to premature mortality in PLWHA. One study estimated PLWHA lose more years from smoking than from HIV infection. In our view, shared by others in the field, the single greatest health behavior change that could improve mortality is to assist smokers living with HIV/AIDS to quit smoking.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Active group and sham groupActive group and sham group
Masking:
Double (Participant, Care Provider)
Masking Description:
Participant will not know whether they receive active or sham TMS
Primary Purpose:
Treatment
Official Title:
Accelerated Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in People Living With HIV/AIDS (PLWHA)
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: TBS (Theta burst stimulation)

Four sessions of TBS in one day

Device: TBS
Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.

Placebo Comparator: Sham TMS

Four sessions of sham TMS

Device: Sham TMS
Four sessions of sham TMS delivered using MagVenture B65 A/P coil.

Outcome Measures

Primary Outcome Measures

  1. Gaze Fixation on Smoking Cues [On Day 1 of the study]

    Measured using an eye tracker which quantifies this in milliseconds, higher score means worse outcome

  2. Gaze Fixation on Smoking Cues [On Day 1 of the study after intervention]

    Measured using an eye tracker which quantifies this in milliseconds, higher score means worse outcome

  3. Craving for cigarettes [On day one of the study.]

    Measured using tobacco craving questionnaire (TCQ), this questionnaire has 12 items. Max score is 48, min score is 0. Higher score means that craving is higher.

  4. Craving for cigarettes [Immediately after intervention (sessions of TBS or sham TMS) on day 1]

    Measured using tobacco craving questionnaire (TCQ), this questionnaire has 12 items. Max score is 48, min score is 0. Higher score means that craving is higher.

Secondary Outcome Measures

  1. Functional connectivity changes [on Day 1 of study]

    Changes in functional connectivity measured using z score on functional MRI brain scan.

  2. Functional connectivity changes [Immediately after intervention (sessions of TBS or sham TMS) on day 1]

    Changes in functional connectivity measured using z score on functional MRI brain scan.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria: Potential participants will be

  • Patients enrolled in the Bluegrass Clinic

  • 18-60 years of age

  • Male or female gender

  • Able to read, understand and communicate in English

  • Willing to adhere to the general rules of the Bluegrass Clinic/SMARTClinic/Beyond Birth Clinic

  • Willing and able to abstain from drug use other than Suboxone

  • Exhaled breath on day of study carbon monoxide (CO) < 5 ppm

  • Stabilized on maintenance buprenorphine if having comorbid opioid use disorder.

Exclusion Criteria:
  • Positive pregnancy test for females, traumatic brain injury, history of seizure disorder, history of or current diagnosis of schizophrenia, intracranial metal shrapnel.

  • Previous adverse effect with TMS.

  • Sub-threshold consistency while performing behavioral tasks.

  • Failure to show baseline attentional bias to smoking versus neutral cues.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Gopalkumar Rakesh

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gopalkumar Rakesh, Assistant Professor, University of Kentucky
ClinicalTrials.gov Identifier:
NCT05295953
Other Study ID Numbers:
  • 70889
First Posted:
Mar 25, 2022
Last Update Posted:
Mar 25, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 25, 2022